From isolated interventions to connected psychiatric care
At the 2026 RANZCP Faculty of Adult Psychiatry Conference in Queenstown, New Zealand, Associate Professor Gary Galambos presented an emerging model of interventional psychiatry that brings together neuroscience, psychological therapies, immersive technologies and digital clinical coordination.
His presentation The Treatment Room of the Future: From Neuromodulation to Connected, Personalised Interventional Psychiatry explored work being undertaken across specialist clinical services in Sydney.
The conference theme, Complexity, Trauma and Neurodiversity in Contemporary Practice provided an appropriate setting for examining why conventional, fragmented approaches to psychiatric care can be difficult to navigate for people with complex presentations.
The central proposition was that the next major advance in psychiatric treatment may come not from a single breakthrough intervention, but from connecting established and emerging treatments into personalised, multidisciplinary pathways of care.
The work presented is already being developed and implemented in selected clinical settings. However, the clinical effectiveness of many of the combined interventions remains under investigation.
Watch video:
The architecture of multimodal interventional psychiatry
The model comprises four interconnected pillars:
- Precision neuromodulation: MRI-guided neuronavigation and transcranial magnetic stimulation.
- AI-personalised therapeutics: Clinician-supervised behavioural activation, exposure and reflective interventions.
- Multisensory immersion: Personalised audiovisual experiences, augmented and virtual reality, and digital scent.
- Connected care: MindSkiller-supported multidisciplinary coordination, treatment planning and outcome measurement.
Caption: Four interconnected pillars provide the framework for multimodal care. Five potential therapeutic layers illustrate how anatomical mapping, TMS, psychological content, immersive experiences and olfactory cues may be selected according to individual clinical needs.
The architecture is a framework for clinical selection, not a prescription that every patient should receive all components simultaneously.
The challenge is to determine which interventions are appropriate for a particular individual, how they should be sequenced, and whether combining them provides meaningful additional benefit.
Pillar 1: MRI-guided precision neuromodulation
Individual anatomy as a starting point
Transcranial magnetic stimulation is a non-invasive intervention that uses magnetic pulses to influence activity in targeted cortical regions.
TMS has an established role in the treatment of treatment-resistant depression, while protocols for OCD and other neuropsychiatric conditions are areas of continuing clinical development.
The Sydney model incorporates high-resolution MRI and neuronavigation to support anatomical targeting.
Rather than relying exclusively on standardised external cranial measurements, clinicians can use individual imaging to identify relevant anatomical landmarks and guide treatment positioning.
For depression, commonly used targets include the dorsolateral prefrontal cortex. OCD protocols may involve medial prefrontal and associated network targets.
Caption: MRI-guided neuronavigation supports individualised anatomical targeting and reproducible TMS positioning. Anatomical precision is one component of a broader clinical formulation and does not, by itself, establish superior clinical outcomes.
This approach offers opportunities to improve anatomical targeting and treatment-positioning consistency. Whether particular navigation methods produce superior outcomes to alternative targeting approaches remains a question for further study.
Integrating psychiatry with radiology
A distinctive feature of the program is the development of MRI-guided TMS services within radiology-based clinical environments.
These include City X-Ray at Martin Place and Beaches X-Ray at Dee Why, through the VisionTMS model.
Caption: The emerging clinical model brings together specialist inpatient and outpatient psychiatric services, consultation rooms and radiology-based neuromodulation facilities across Sydney.
Bringing radiology, neurology and psychiatry into closer collaboration provides opportunities to integrate imaging expertise, anatomical mapping and specialist treatment delivery.
It also illustrates how private healthcare services can contribute to the development of multidisciplinary interventional psychiatry.
Pillar 2: AI-Personalised Immersive Therapeutics
Psychiatric symptoms are experienced within the context of an individual's memories, relationships, values, fears and aspirations.
AI-Personalised Immersive Therapeutics (AI-PIT) explores how clinician-supervised AI tools can assist in creating therapeutic material informed by these individual characteristics.
The intention is not to automate psychotherapy or replace clinical formulation.
It is to support the development of psychological content that is personally meaningful, adaptable and capable of being incorporated into a structured treatment pathway.
AI-BEAT: Behavioural and Emotional Activation
Behavioural activation is an established psychological approach used in depression treatment.
AI-BEAT explores how personally meaningful images, narratives, activities and memories might be incorporated into behavioural and emotional activation experiences.
A patient might reconnect with an activity they once enjoyed, an important relationship or a goal they wish to pursue.
AI-assisted content creation allows clinicians to develop material reflecting these individual experiences.
The clinical question is whether this degree of personalisation can improve engagement, acceptability or outcomes when incorporated into an appropriately supervised treatment program.
AI-ERP: Exposure and Response Prevention
Exposure and response prevention is a core evidence-based psychological treatment for OCD.
AI-ERP explores how personalised audiovisual content can support clinician-guided exposure exercises.
Scenarios can be developed around particular obsessional fears and compulsive behaviours, including contamination, checking, mistakes and responsibility.
Digital environments may provide repeatable exposure opportunities that can be adjusted according to the patient's formulation and treatment progress.
The essential therapeutic process remains exposure with prevention of compulsive responses. Digital content is an adjunct, not a substitute for competent ERP.
The integration of ERP with neuromodulation is being investigated, but any additional benefit from combining these interventions must be established through appropriate research.
AI-REFLECT: Reflection and Consolidation
AI-REFLECT is designed to support therapeutic reflection and continuity.
Personalised audiovisual material can help patients review experiences, recognise progress, reconnect with treatment goals and consider the next steps in care.
The approach may be particularly relevant within longitudinal treatment programs, where continuity between individual sessions and later follow-up is important.
Pillar 3: Multisensory immersion
The third pillar explores the therapeutic possibilities of integrating visual, auditory and olfactory experiences.
Psychological interventions frequently rely on imagination, verbal description and real-world experiences.
Digital technologies offer additional ways of presenting carefully structured therapeutic scenarios.
Two-dimensional, virtual and augmented reality
Two-dimensional exposure scenes, virtual reality and augmented reality glasses can provide environments relevant to particular therapeutic goals.
For OCD, a personalised digital scenario may support clinician-guided exposure.
For behavioural activation, audiovisual content may represent activities or environments with positive personal significance.
These technologies also raise practical questions about tolerability, sensory sensitivity, treatment fidelity and clinical supervision.
Their use should be guided by individual assessment rather than technological novelty.
Synchronised digital scent
An emerging component of the program involves programmable olfactory stimulation using the Aroma Shooter 2.
The device allows selected scents to be delivered in coordination with audiovisual experiences.
Because olfaction is closely associated with memory and emotion, scent is an interesting candidate for investigation within personalised therapeutic environments.
Potential applications include contextual cues during behavioural activation and selected exposure exercises.
However, the incremental therapeutic value of adding scent has not been established by these early implementations.
The program therefore treats olfactory integration as an area for systematic clinical evaluation.
Pillar 4: MindSkiller® and connected multidisciplinary care
The development of increasingly sophisticated treatment options creates a new operational challenge.
How can multiple clinicians, interventions and clinical settings be coordinated around the needs of one patient?
Without effective coordination, multimodal care risks reproducing the fragmentation it is intended to address.
MindSkiller® is being developed as digital infrastructure to support connected clinical workflows.
The platform incorporates clinical forms, assessments, multidisciplinary team functions, treatment planning tools and longitudinal outcome measurement.
Its purpose is to help clinicians organise care around a shared treatment pathway while retaining appropriate professional responsibilities and privacy safeguards.
TMS Plus: Individualised treatment packages
The TMS Plus model applies these principles through structured treatment packages.
Depending on the patient's needs, a package may incorporate specialist consultations, MRI-guided TMS, personalised psychological content, immersive interventions and follow-up monitoring.
The treatment components and their sequencing are determined through clinical assessment.
A patient with treatment-resistant depression may have different requirements from someone undertaking an OCD-focused program.
The aim is not to create a uniform technological treatment package.
It is to provide a framework through which individual interventions can be selected, coordinated and evaluated.
Research and governance: U-INSPIRE and O-INSPIRE
Responsible innovation requires more than demonstrating that new interventions can be delivered.
It requires examining whether they are feasible, acceptable, tolerable, safe and clinically useful.
The U-INSPIRE and O-INSPIRE programs provide frameworks for evaluating aspects of these emerging approaches within real-world inpatient and outpatient settings.
The programs aim to examine clinical outcomes and patient experiences while supporting systematic collection of longitudinal information.
Their naturalistic designs are intended to generate evidence about real-world clinical practice, rather than establish the causal efficacy of individual treatment components.
Preliminary OCD observations
The Queenstown presentation included preliminary longitudinal Yale-Brown Obsessive Compulsive Scale (Y-BOCS) trajectories from individuals undergoing multimodal treatment.
These observations illustrate symptom changes over time and demonstrate the value of structured outcome tracking.
They do not establish causal efficacy, the superiority of combined treatment or the contribution of individual components.
An important objective of future research is to identify which interventions or combinations may be useful for particular patient profiles, and whether any benefits persist beyond the initial treatment period.
The challenges of implementation
Developing multimodal interventional psychiatry involves significant clinical, technological and organisational challenges.
These include:
- Ensuring appropriate clinical supervision of AI-generated therapeutic content.
- Protecting sensitive patient information and obtaining meaningful consent.
- Managing sensory tolerability and individual responses to immersive interventions.
- Maintaining consistent treatment delivery across clinicians and locations.
- Evaluating the effectiveness and cost of complex treatment combinations.
- Developing models that are practical, affordable and scalable.
These considerations are not secondary to innovation.
They are central to determining whether an emerging clinical model can be implemented responsibly and sustainably.
From fragmented to connected psychiatry
The underlying ambition is to move beyond a system in which biological treatments, psychological therapies, clinical documentation and outcome measurement operate largely independently.
Connected interventional psychiatry seeks to organise these components into an individualised pathway.
The potential benefits include improved coordination, clearer treatment planning, more consistent measurement and opportunities to study how different interventions interact.
Whether this approach produces better patient outcomes, and under what circumstances, remains a critical research question.
The human element
The treatment room of the future is not defined by the number of technologies it contains.
A neuronavigation system cannot replace clinical judgement.
An AI-generated therapeutic video is not a therapeutic relationship.
An immersive environment does not remove the need for careful assessment, consent or skilled psychological treatment.
The goal is to use these technologies in ways that support clinicians and make treatment more personally meaningful for patients.
This work depends on collaboration across psychiatry, neurology, psychology, nursing, radiology, software development and clinical research.
We acknowledge the contributions of colleagues across Uspace at St Vincent's Private Hospital Sydney, VisionTMS, TMS Plus, MindSkiller and the associated research and development teams.
Looking ahead
The clinical work presented at Queenstown demonstrates how precision neuromodulation, personalised psychological therapeutics, immersive technologies and digital coordination can begin to operate within a connected model of psychiatric care.
The next challenge is to establish when these combinations are useful, how they can be delivered sustainably, and what measurable benefits they provide.
The most important innovation may not be any single device, software application or treatment protocol.
It may be the ability to connect neuroscience, psychological understanding and multidisciplinary clinical care into a coherent therapeutic journey designed around the individual patient.
Further reading: From Neuromodulation to Connected, Personalised Interventional Psychiatry: Reflections on My Queenstown 2026 Lecture — Associate Professor Gary Galambos: www.DrGaryGalambos.com